An open-access review published on 1 October 2026 in the journal Collagen and Leather argues that collagen recovered from meat, leather and seafood processing by-products could be a source of blood-pressure-lowering peptides, in a field where roughly 1.4 billion adults aged 30 to 79 have hypertension and only about 21 percent have it adequately controlled.

The raw material does nothing on its own. Native collagen molecules weigh 285 to 300 kilodaltons, are largely insoluble and are described in the review as biologically inert. Controlled enzymatic hydrolysis chops them into fragments of roughly 3 to 6 kilodaltons, releasing short sequences small enough to be absorbed and shaped to bind angiotensin-converting enzyme, or ACE, the enzyme that synthetic blood pressure drugs target.

Processing beats provenance

The most useful finding here is also the least glamorous. Pooling 47 characterized peptides from bovine, porcine, poultry and marine sources, the authors conclude that enzyme selection, hydrolysis time, enzyme-to-substrate ratio and deactivation conditions determine bioactivity more than the animal the collagen came from. That cuts against most collagen marketing, which sells the species on the label.

The animal data and the human data

The headline numbers are from rats. Two bovine peptides lowered systolic blood pressure by 31.3 and 38.6 millimeters of mercury in spontaneously hypertensive rats after oral dosing, with effects lasting beyond eight hours. Human results are far smaller: a meta-analysis by Jalili and colleagues pooling twelve randomized controlled trials found a systolic reduction of 5.04 millimeters of mercury after collagen peptide supplementation. A trial giving 2 grams daily to healthy normotensive volunteers found no change at all, which the authors read as the peptides correcting pathological elevation rather than lowering pressure indiscriminately.

Where the evidence stops

That meta-analysis carried very high heterogeneity, an I squared of 98.9 percent, reflecting wildly variable preparations, doses and populations. The longest human intervention ran six months, and no trial has tested whether these peptides reduce heart attacks or strokes rather than the surrogate endpoint of blood pressure.

Bottom line

The review positions collagen peptides as a candidate adjunct for mild to moderate hypertension, not a replacement for anything. Its sharpest practical point is that two tubs labeled collagen hydrolysate can carry entirely different peptide profiles, and nobody is currently required to say so.